Diabetes Care in the Hospital Setting: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
! [[Patient]] status !! Mild [[hyperglycaemia]] !! Moderate [[hyperglycaemia]] !! Severe [[hyperglycaemia]]
! [[Patient]] status !! Mild [[hyperglycaemia]] !! Moderate [[hyperglycaemia]] !! Severe [[hyperglycaemia]]
|-
|-
| Definition || [[blood sugar|Blood glucose]] < 200 <br> [[Patients]] who are taking less than 2 [[anti-diabetic drug]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] || 201 < [[blood sugar|Blood glucose]] <300 <br> [[Patients]] who are taking multiple [[anti-diabetic drug]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] <br> [[Patients]] who are taking less than 0·6 U/kg [[insulin]] per day || [[blood sugar|Blood glucose]] > 301 <br> [[Patients]] who are taking multiple [[anti-diabetic drug]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] <br> [[Patients]] who are taking more than 0·6 U/kg [[insulin]] per day
! Definition  
| [[blood sugar|Blood glucose]] < 200 <br> [[Patients]] who are taking less than 2 [[anti-diabetic drugs]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] || 201 < [[blood sugar|Blood glucose]] <300 <br> [[Patients]] who are taking multiple [[anti-diabetic drug]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] <br> [[Patients]] who are taking less than 0·6 U/kg [[insulin]] per day || [[blood sugar|Blood glucose]] > 301 <br> [[Patients]] who are taking multiple [[anti-diabetic drug]] (such as [[mouth|oral]] [[anti-diabetic drug]] or [[Glucagon-like peptide 1 receptor|GLP-1 receptor agonists]] <br> [[Patients]] who are taking more than 0·6 U/kg [[insulin]] per day
|-
|-
|Approach || Low dose [[Basal (medicine)|basal]] [[insulin]] OR [[mouth|oral]] [[anti-diabetic drug]]†, if there are no [[contraindications]]. <br> Further [[blood sugar|blood glucose]] correction can be applied by rapid-acting [[insulin]] (before meals or every 6 hours) || [[Basal (medicine)|Basal]] [[insulin]] OR [[mouth|oral]] [[anti-diabetic drug]]†, if there are no [[contraindications]]. <br> Initial [[insulin]] dose: 0·2–0·3 U/kg per day (start from 0·15 U/kg per day (if using [[Basal (medicine)|basal]] [[insulin]] alone) or 0·3 U/kg per day (if using [[Basal (medicine)|basal]]–bolus) for [[patients]] with high risk of [[hypoglycemia]]). <br> Further [[blood sugar|blood glucose]] correction can be applied by rapid-acting [[insulin]] (before meals or every 6 hours) || [[Basal (medicine)|Basal]]–bolus [[insulin]] regimen <br> Initial [[insulin]] dose: Reduce [[patient]]'s home [[insulin]] regimen by 20% OR 0·3 U/kg per day (half [[Basal (medicine)|basal]] and half bolus]] <br> If [[patient]] has poor intake, hold the prandial [[insulin]].
! Approach  
| Low dose [[Basal (medicine)|basal]] [[insulin]] OR [[mouth|oral]] [[anti-diabetic drug]]†, if there are no [[contraindications]]. <br> Further [[blood sugar|blood glucose]] correction can be applied by rapid-acting [[insulin]] (before meals or every 6 hours) || [[Basal (medicine)|Basal]] [[insulin]] OR [[mouth|oral]] [[anti-diabetic drug]]†, if there are no [[contraindications]]. <br> Initial [[insulin]] dose: 0·2–0·3 U/kg per day (start from 0·15 U/kg per day (if using [[Basal (medicine)|basal]] [[insulin]] alone) or 0·3 U/kg per day (if using [[Basal (medicine)|basal]]–bolus) for [[patients]] with high risk of [[hypoglycemia]]). <br> Further [[blood sugar|blood glucose]] correction can be applied by rapid-acting [[insulin]] (before meals or every 6 hours) || [[Basal (medicine)|Basal]]–bolus [[insulin]] regimen <br> Initial [[insulin]] dose: Reduce [[patient]]'s home [[insulin]] regimen by 20% OR 0·3 U/kg per day (half [[Basal (medicine)|basal]] and half bolus]] <br> If [[patient]] has poor intake, hold the prandial [[insulin]].
|}
|}
<sub>†One of the options which has been studied in [[randomised controlled trials]] is [[dipeptidyl peptidase-4 inhibitor]]. Although [[metformin]] use is common, use with caution due to high risk of lactic acidosis, especially in high risk [[patients]] (such as [[sepsis]], [[renal insufficiency]], [[shock]] and [[hepatic failure]])</sub>
<sub>†One of the options which has been studied in [[randomised controlled trials]] is [[dipeptidyl peptidase-4 inhibitor]]. Although [[metformin]] use is common, use with caution due to high risk of lactic acidosis, especially in high risk [[patients]] (such as [[sepsis]], [[renal insufficiency]], [[shock]] and [[hepatic failure]])</sub>

Revision as of 07:34, 25 April 2021

2016 ADA Guideline Recommendations

Types of Diabetes Mellitus

Main Diabetes Page

Diabetes type I

Diabetes type II

Gestational Diabetes Mellitus

2016 ADA Standard of Medical Care Guideline Recommendations

Strategies for Improving Care

Classification and Diagnosis of Diabetes

Foundations of Care and Comprehensive Medical Evaluation

Diabetes Self-Management, Education, and Support
Nutritional Therapy

Prevention or Delay of Type II Diabetes

Glycemic Targets

Obesity Management for Treatment of Type II Diabetes

Approaches to Glycemic Treatment

Cardiovascular Disease and Risk Management

Hypertension and Blood Pressure Control
Lipid Management
Antiplatelet Agents
Coronary Heart Disease

Microvascular Complications and Foot Care

Diabetic Kidney Disease
Diabetic Retinopathy
Diabetic Neuropathy
Diabetic Footcare

Older Adults with Diabetes

Children and Adolescents with Diabetes

Management of Cardiovascular Risk Factors in Children and Adolescents with Diabetes
Microvascular Complications in Children and Adolescents with Diabetes

Management of Diabetes in Pregnancy

Diabetes Care in the Hospital Setting

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]; Tarek Nafee, M.D. [3]

Key studies include:


Patient status Mild hyperglycaemia Moderate hyperglycaemia Severe hyperglycaemia
Definition Blood glucose < 200
Patients who are taking less than 2 anti-diabetic drugs (such as oral anti-diabetic drug or GLP-1 receptor agonists
201 < Blood glucose <300
Patients who are taking multiple anti-diabetic drug (such as oral anti-diabetic drug or GLP-1 receptor agonists
Patients who are taking less than 0·6 U/kg insulin per day
Blood glucose > 301
Patients who are taking multiple anti-diabetic drug (such as oral anti-diabetic drug or GLP-1 receptor agonists
Patients who are taking more than 0·6 U/kg insulin per day
Approach Low dose basal insulin OR oral anti-diabetic drug†, if there are no contraindications.
Further blood glucose correction can be applied by rapid-acting insulin (before meals or every 6 hours)
Basal insulin OR oral anti-diabetic drug†, if there are no contraindications.
Initial insulin dose: 0·2–0·3 U/kg per day (start from 0·15 U/kg per day (if using basal insulin alone) or 0·3 U/kg per day (if using basal–bolus) for patients with high risk of hypoglycemia).
Further blood glucose correction can be applied by rapid-acting insulin (before meals or every 6 hours)
Basal–bolus insulin regimen
Initial insulin dose: Reduce patient's home insulin regimen by 20% OR 0·3 U/kg per day (half basal and half bolus]]
If patient has poor intake, hold the prandial insulin.

†One of the options which has been studied in randomised controlled trials is dipeptidyl peptidase-4 inhibitor. Although metformin use is common, use with caution due to high risk of lactic acidosis, especially in high risk patients (such as sepsis, renal insufficiency, shock and hepatic failure)


2016 ADA Standards of Medical Care in Diabetes Guidelines

"1. Consider performing an A1C on all patients with diabetes or hyperglycemia admitted to the hospital if not performed in the previous 3 months. (Level of Evidence: C)"
"2. Insulin therapy should be initiated for treatment of persistent hyperglycemia starting at a threshold ≥180 mg/dL (10.0 mmol/L). Once insulin therapy is started, a target glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for the majority of critically ill patients(Level of Evidence: A)and noncritically ill patients (Level of Evidence: C)"
"3. More stringent goals, such as 110–140 mg/dL (6.1–7.8 mmol/L) may be ap- propriate for selected critically ill patients, as long as this can be achieved without significant hypoglycemia (Level of Evidence: C)"
"4. Intravenous insulin infusions should be administered using validated written or computerized protocols that allow for predefined adjustments in the insulin infusion rate based on glycemic fluctuations and insulin dose. (Level of Evidence: E)"
"5. A basal plus bolus correction insulin regimen is the preferred treatment for noncritically ill patients with poor oral intake or those who are taking nothing by mouth. An insulin regimen with basal, nutritional, and correction components is the preferred treatment for patients with good nutritional intake. (Level of Evidence: A)"
"6. The sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged (Level of Evidence: A)"
"7. A hypoglycemia management protocol should be adopted and implemented by each hospital or hospital system. A plan for preventing and treating hypoglycemia should be established for each patient. Episodes of hypoglycemia in the hospital should be documented in the medical record and tracked. (Level of Evidence: E)"
"8. The treatment regimen should be reviewed and changed if necessary to prevent further hypoglycemia when a blood glucose value is <70 mg/dL (3.9 mmol/L). (Level of Evidence: C)"
"9. There should be a structured discharge plan tailored to the individual patient. (Level of Evidence: B)"


References

  1. Christensen MB, Gotfredsen A, Nørgaard K (2017). "Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: A systematic review and meta-analysis". Diabetes Metab Res Rev. 33 (5). doi:10.1002/dmrr.2885. PMID 28067472.
  2. Gómez Cuervo C, Sánchez Morla A, Pérez-Jacoiste Asín MA, Bisbal Pardo O, Pérez Ordoño L, Vila Santos J (2016). "Effective adverse event reduction with bolus-basal versus sliding scale insulin therapy in patients with diabetes during conventional hospitalization: Systematic review and meta-analysis". Endocrinol Nutr. 63 (4): 145–56. doi:10.1016/j.endonu.2015.11.008. PMID 26826772.
  3. American Diabetes Association (2018). "14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018". Diabetes Care. 41 (Suppl 1): S144–S151. doi:10.2337/dc18-S014. PMID 29222385.
  4. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM; et al. (2012). "Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline". J Clin Endocrinol Metab. 97 (1): 16–38. doi:10.1210/jc.2011-2098. PMID 22223765.
  5. 5.0 5.1 Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C; et al. (2013). "Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial". Diabetes Care. 36 (8): 2169–74. doi:10.2337/dc12-1988. PMC 3714500. PMID 23435159.
  6. Zaman Huri H, Permalu V, Vethakkan SR (2014). "Sliding-scale versus basal-bolus insulin in the management of severe or acute hyperglycemia in type 2 diabetes patients: a retrospective study". PLoS One. 9 (9): e106505. doi:10.1371/journal.pone.0106505. PMC 4152280. PMID 25181406.
  7. Bueno E, Benitez A, Rufinelli JV, Figueredo R, Alsina S, Ojeda A; et al. (2015). "BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA". Endocr Pract. 21 (7): 807–13. doi:10.4158/EP15675.OR. PMID 26121460.
  8. Newsom R, Patty C, Camarena E, Sawyer R, McFarland R, Gray T; et al. (2018). "Safely Converting an Entire Academic Medical Center From Sliding Scale to Basal Bolus Insulin via Implementation of the eGlycemic Management System". J Diabetes Sci Technol. 12 (1): 53–59. doi:10.1177/1932296817747619. PMC 5761993. PMID 29237289.
  9. 9.0 9.1 9.2 9.3 9.4 Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE (2021). "Management of diabetes and hyperglycaemia in the hospital". Lancet Diabetes Endocrinol. 9 (3): 174–188. doi:10.1016/S2213-8587(20)30381-8. PMID 33515493 Check |pmid= value (help).
  10. NICE-SUGAR Study Investigators. Finfer S, Chittock DR, Su SY, Blair D, Foster D; et al. (2009). "Intensive versus conventional glucose control in critically ill patients". N Engl J Med. 360 (13): 1283–97. doi:10.1056/NEJMoa0810625. PMID 19318384. Review in: J Fam Pract. 2009 Aug;58(8):424-6 Review in: Ann Intern Med. 2009 Aug 18;151(4):JC2-5

Template:WHTemplate:WS